Chris Singer, president of the International Section of the Pharmaceutical Research and Manufacturers of America, issued the following statement today on the U.S. Trade Representative’s (USTR) "Special 301" annual report to Congress, outlining the Administration’s global intellectual property agenda:
“Maintaining global incentives for research and development of new medicines is essential for the continued innovation of treatments that help improve ...
Satisfied Users & 
Approved Press Releases
